PhaseBio Pharmaceuticals EV/FCF

EV/FCF of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current EV/FCF of PhaseBio Pharmaceuticals is -1.38 (as of December 30, 2020)
  • EV/FCF for the quarter ending September 29, 2021 was -2.57 (a 1.07% increase compared to previous quarter)
  • Year-over-year quarterly EV/FCF decreased by -3.91%
  • Annual EV/FCF for 2020 was -1.38 (a -48.44% decrease from previous year)
  • Annual EV/FCF for 2019 was -2.68 (a -235.2% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of PhaseBio Pharmaceuticals

Most recent EV/FCFof PHAS including historical data for past 10 years.

Interactive Chart of EV/FCF of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -2.57 -2.55
2020 -0.9 -1.38
2019 -2.68 -1.37 -10.3 -11.08 -2.68
2018 1.98 1.03 1.98

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.